Newsgroup: it.economia.borsa.estero
Titolo: OXGN Ecco BeatoOne, se la vuoi

vedere risalire a razzo, scrivi le parole TAKE OVER nel board di Yahoo

 vedere risalire a razzo, scrivi le parole TAKE OVER nel board di Yahoo
Sembra l'unica ragione possibile visto che la notizia della sperimentazione
di una nuova terapia chemioterapica nei casi di tumore ovarico non
giustificherebbe una serie imili di rialzi.
Insomma non è stata scoperta nessuna cura per il tumore.
Resta da chiedersi...domani che succederà?

se è un take over, a brevissimo sale per poi riscendere. (Ma dovrebbero aver
già comunicato alla SEC)
E' un movimento finanziario, non c'entra niente col core business
se invece è altro...............
bisogna saperlo subito..........
leggi, leggi, leggi e ricerca, ricerca, ricerca...
nel caso posta il risultato delle ricerche

no va, c'è qualcosa che non torna
ma non è che sbaglio i conti ? dunque :
c'è stato scambio per 380 milioni di dollari e la società capitalizza 178
milioni
dov'è che sbaglio ?

 ha scritto nel messaggio
news:T97Fa.66233$pR3.1...@news1.tin.it...

Innanzitutto qua c'è qualcosa che potrebbbe fare un po' + di luce su ciò di
cui la Oxigene si occupa. Buona lettura...  La notizia risale al 23/Dic/2003
OXiGENE announces phase II clinical trial of lead anti-tumor compound in
thyroid cancer
Company's Combretastatin A4 Prodrug becomes the first vascular targeting
agent to advance to phase II
WATERTOWN, Mass--Dec. 23, 2002-- OXiGENE, Inc. (Nasdaq: OXGN, SSE: OXGN),
today announced the start of a Phase II clinical trial for its lead vascular
targeting agent (VTA), a tumor-starving compound called Combretastatin A4
Prodrug (CA4P), in patients with a rare and often incurable form of thyroid
cancer. OXiGENE is the world's first biopharmaceutical firm whose VTA has
advanced to a Phase II human trial.
Approximately 32 patients are expected to be enrolled in the study, which
will be conducted at the Ireland Cancer Center at University Hospitals of
Cleveland. The trial was cleared by the U.S. Food and Drug Administration
and the hospital's Investigational Review Board.
Researchers will evaluate CA4P's effectiveness in extending the survival of
patients with advanced anaplastic carcinoma of the thyroid (ATC). A key
objective will be to determine whether CA4P can double to 12 months the
median survival of patients with advanced stages of the disease. ATC is an
extremely aggressive disease with a poor prognosis and no established
standard treatment therapy.
OXiGENE completed Phase I safety trials of CA4P in 2001. During those
trials, one patient with ATC, who had exhausted all known treatment regimens
used for this disease, responded completely to CA4P as a single-agent
treatment. The patient has now been disease free for more than 36 months.
Four other Phase I patients with other forms of thyroid cancer experienced
various lengths of disease stabilization following CA4P treatments.
"In both animal models and Phase I human clinical studies, CA4P has
demonstrated the ability to selectively target existing tumor vasculature,
in essence starving the tumor by blocking the flow of blood that supplies it
with oxygen and nutrients," said OXiGENE President and CEO Fred Driscoll.
"Shepherding the compound into a Phase II trial is the most significant
milestone for our company to date, and reinforces our position as the leader
in this emerging area of cancer therapy."
"The pre-clinical and early clinical experience of CA4P makes the compound
extremely well-suited for study in Phase II," said the trial's lead
investigator, Scot C. Remick, M.D., Associate Professor of Medicine and
International Health at University Hospitals of Cleveland and Case Western
Reserve University School of Medicine. "Based on our Phase I experience, we
are very pleased to continue development of this compound for the treatment
of ATC. This clinical trial offers a unique opportunity to investigate a
novel anti-tumor treatment, and to potentially establish CA4P as a new
therapy."
In addition to the trial announced today, a Phase Ib trial of CA4P is
underway at the University of Pennsylvania's Presbyterian Medical Center,
where researchers are studying the VTA in combination with a chemotherapy
drug called Carboplatin.
CA4P attacks the vascular structure of solid tumors and other diseases
characterized by the formation of aberrant blood vessels. The compound
triggers a change in the shape of endothelial cells lining a tumor's blood
vessels. This in turn blocks the flow of blood to the tumor, depriving it of
oxygen and nutrients. The compound is a synthetic form of CA4, a natural
substance found in the bark of the South African willow tree known as
combretum caffrum. CA4 was identified and isolated in 1987 by Professor G.
Robert Pettit, director of the Cancer Research Institute at Arizona State
University.
"Our Phase II study represents an opportunity to assess the preliminary
efficacy of CA4P in a specific indication," said Dai Chaplin, Ph.D.,
OXiGENE's chief scientific officer. "This is particularly exciting because
our Phase I study resulted in a complete pathological response in a patient
with the identical disease."
###
About OXiGENE
OXiGENE is the world leader in the development of vascular targeting agents
that attack existing blood vessels associated with cancerous tumors and may
have applications in certain forms of ocular disease and other conditions.
OXiGENE is using its proprietary vascular targeting technology to develop
new drugs designed to enhance the effectiveness of traditional cancer
treatments and to introduce innovative therapies that attack cancer and
other diseases. For more information about OXiGENE, visit 
www.oxigene.com
.
Safe Harbor Statement
This news release about OXiGENE's Phase II trial of CA4P contains
"forward-looking" statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include, but are not limited
to: the number of patients to be enrolled in the trial; the objectives of
the trial; the suitability of the compound for advanced study; the potential
to define a new standard of care for the treatment of ATC; the potential
efficacy of CA4P; CA4P's ability to enable development of normal blood
vessels and/or inhibit the growth of aberrant vasculature; the efficacy of
OXiGENE's vascular targeting agents in treating cancerous tumors; OXiGENE's
ability to develop new drugs that will enhance the effectiveness of
traditional cancer treatments; and OXiGENE's ability to introduce innovative
therapies that attack cancer and other diseases. Any or all of the
forward-looking statements in this press release may turn out to be wrong.
They can be affected by inaccurate assumptions we might make or by known or
unknown risks and uncertainties, including, but not limited to: the ability
to successfully enroll patients in the trial; the early stage of product
development; uncertainties as to the future success of ongoing and planned
clinical trials; and the unproven safety and efficacy of products under
development. Consequently, no forward-looking statement can be guaranteed,
and actual results may vary materially. Additional information concerning
factors that could cause actual results to materially differ from those in
the forward-looking statements is contained in OXiGENE's reports to the
Securities and Exchange Commission, including OXiGENE's 10-Q, 8-K and 10-K
reports. However, OXiGENE undertakes no obligation to publicly update
forward-looking statements, whether as a result of new information, future
events or otherwise.

 ha scritto nel messaggio
news:T97Fa.66233$pR3.1...@news1.tin.it...

E qui c'è una press release di oggi, quella già pubblicata ma qui nella
versione estesa e completa
WATERTOWN, Mass.--(BUSINESS WIRE)--June 9, 2003--
          Fourth Concurrent Clinical Trial of Company's Lead
                        Tumor-Starving Compound
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today that its lead
Vascular Targeting Agent (VTA), Combretastatin A4 Prodrug (CA4P), will be
combined with two standard-of-care chemotherapy drugs in a new clinical
trial involving patients with advanced ovarian cancer.
CA4P will be studied in combination with carboplatin and paclitaxel in a
Phase I/II trial that is being launched at Mount Vernon Hospital in the
United Kingdom. The trial protocol has been approved by the U.K.'s health
regulatory authority, the Medicines Control Agency, as well as the
hospital's Institutional Ethics Committee. The Phase I arm of the study,
which will include roughly 30 patients, will assess the safety and
tolerability of the combination and will establish the optimal dosing
schedule. The Phase II arm, which is expected to include between 20 and 30
patients, will focus on collecting additional safety data and evaluating
anti-tumor efficacy.
"While radiation, chemotherapy and surgery have enabled medical
professionals to manage cancer more effectively, the fact remains that many
solid tumors remain incurable," said the study's principal investigator,
Gordon Rustin, M.D., director of the Department of Medical Oncology at Mount
Vernon Hospital. "This trial presents an opportunity to study the most
clinically advanced Vascular Targeting Agent - CA4P - with two drugs that
are considered the established standard of chemotherapy treatment in ovarian
cancer."
"Our drug development program continues to build momentum," said Fred
Driscoll, OXiGENE's president and CEO. "Over the past 12 months, CA4P has
progressed into four clinical trials in five distinct tumor types -
anaplastic thyroid, head & neck, lung, prostate and, now, ovarian - which
are expected to account for more than 445,000 new cancer cases in the U.S.
in 2003. The breadth of clinical evaluation of CA4P truly reflects the level
of interest in the compound as an anti-cancer therapy."
Ovarian cancer ranks second in the number of new cases per year among the
gynecologic cancers, according to the American Cancer Society (ACS).
However, ovarian cancer causes more deaths per year than any other cancer of
the female reproductive system. The ACS estimates that, in 2003, 14,300
ovarian cancer deaths will occur in the U.S. and another 25,400 women will
be diagnosed with the disease.
OXiGENE announced last week that the U.S. Food and Drug Administration (FDA)
granted "fast track" designation to CA4P for the treatment of advanced
anaplastic thyroid cancer (ATC). CA4P currently is being evaluated in a
Phase II study of patients with this disease.
In addition to the Phase I/II trial announced today and the Phase II study
of patients with ATC, CA4P is being evaluated in a Phase I/II combination
study with radiotherapy in patients with malignancies of the lung, head &
neck and prostate; and a Phase Ib combination study with carboplatin in
patients with various solid tumors. Although the carboplatin trial is
ongoing and patients are still receiving therapy, there is no further
patient accrual as the study objectives have been achieved. The data already
obtained from the carboplatin study is being used in the design of this new,
more advanced trial combining CA4P with carboplatin and paclitaxel.
CA4P is the water-soluble prodrug of Combretastatin A4, a compound isolated
from the African bush willow Combretum Caffrum. CA4P is designed to damage
and destroy solid tumors by impeding the flow of blood that carries the
oxygen and nutrients these tumors need to grow and thrive. Research suggests
that CA4P works by disrupting the intricate network of endothelial cells
lining the tumor blood vessels, in essence killing the tumor from the
inside. In Phase I trials, CA4P demonstrated biological effect with a
complete patient response in anaplastic thyroid carcinoma and a partial
response in fibrosarcoma. Several other Phase I patients with colon,
medullary thyroid and pancreatic cancer saw prolonged periods of disease
stabilization.
About OXiGENE
OXiGENE is the world leader in the development of novel biopharmaceutical
compounds called vascular targeting agents (VTAs), which are designed to
block the flow of blood that supplies solid cancer tumors and other abnormal
vasculature, while leaving healthy cells intact. The Company's VTAs may have
application in the treatment of certain forms of ocular disease and other
conditions. OXiGENE's lead VTA, Combretastatin A4 Prodrug, has advanced into
Phase II and combination clinical trials in cancer patients in the United
States and Europe. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007,
are in pre-clinical development. For more information about OXiGENE, visit
www.oxigene.com
.
Safe Harbor Statement
This news release about the Phase I/II combination trial of CA4P,
carboplatin and paclitaxel contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements include, but are not limited to: the number of patients expected
to be enrolled in each arm of the study; the study's objectives; the
expected number of new cases of lung, prostate, head & neck and ovarian
cancer in the U.S. in 2003; the ability of OXiGENE's vascular targeting
compounds to enhance the effectiveness of traditional cancer treatments; and
the introduction of innovative therapies to attack cancer and other
diseases. Any or all of the forward-looking statements in this press release
may turn out to be wrong. They can be affected by inaccurate assumptions
OXiGENE might make or by known or unknown risks and uncertainties,
including, but not limited to: the early stage of product development; the
ability to secure necessary patents; uncertainties as to the future success
of ongoing and planned clinical trials; and the unproven safety and efficacy
of products under development. Consequently, no forward-looking statement
can be guaranteed, and actual results may vary materially. Additional
information concerning factors that could cause actual results to materially
differ from those in the forward-looking statements are contained in
OXiGENE's reports to the Securities and Exchange Commission, including
OXiGENE's 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no
obligation to publicly update forward-looking statements, whether because of


letto veloce mi sembra siano solo sperimentazioni.
Sono centinaia le societą con simili notizie
La fase I parla di un solo paziente
no, non credo sia solo questo. Anche perchč sarebbe su tutti i media
c'č altro secondo me

 ha scritto nel messaggio
news:Qg7Fa.66297$pR3.1...@news1.tin.it...

Io sono un niubbo quindi non mi avventuro in interpretazioni di sorta.
Mi interesserebbe capire com'è possibile?

insisto, ho la sensazione che si tratti di operazione finanziaria